Over 25% of weight lost from GLP-1 drugs or bariatric surgery comes from fat-free mass including muscle and bone, but emerging myostatin/activin inhibitors like bimagrumab could preserve lean mass during weight loss.
>25% is muscle/bone lossMore than a quarter of weight lost from both GLP-1 drugs and bariatric surgery comes from fat-free mass — a significant but often overlooked risk that emerging myostatin inhibitors could address
What the researchers found
Over 25% of total weight lost from both bariatric surgery and GLP-1 pharmacotherapy comes from fat-free mass. The myostatin-activin-follistatin system is crucial for lean mass preservation during negative energy balance. Bimagrumab, trevogrumab, and garetosmab inhibit activin/myostatin signaling and show promise in preventing muscle loss while promoting fat loss, either alone or combined with incretin receptor agonists.
Why it matters
As GLP-1 drugs become the standard for obesity treatment, the quality of weight loss — not just the quantity — becomes critical. Losing 25% or more of weight as muscle can accelerate aging, reduce metabolic rate, increase fall risk, and create a cycle of weight regain. Combining fat-targeting and muscle-preserving drugs could fundamentally improve obesity treatment outcomes.
The numbers in context
Weight loss of 15-25% is common. Over 25% of weight lost is fat-free mass. Both surgical and pharmacological approaches show this pattern.
How the study worked
Narrative review synthesizing evidence on body composition changes during weight loss (surgical and pharmacological), the biology of the myostatin-activin-follistatin system, and the clinical pipeline of muscle-preserving compounds for combination with anti-obesity medications.
Who was studied
Patients losing weight through bariatric surgery or incretin-based pharmacotherapy
What this study cannot tell us
Narrative review format without systematic evidence assessment. Myostatin inhibitor clinical data is still limited — most are in early to mid-stage trials. Long-term safety of combined incretin + myostatin inhibitor therapy is unknown. The 25% fat-free mass loss figure varies significantly across studies and individual patients.
How to read the evidence
Strong evidence for the problem (muscle loss during weight loss is well-documented across multiple studies). Preliminary evidence for the proposed solution (myostatin inhibitor combination therapy is in early clinical stages).
When this study was published
Published in 2024, addressing a timely concern as GLP-1 RA prescribing accelerates and clinicians encounter more patients with significant muscle loss.
The bigger picture
The obesity drug revolution is creating a new clinical problem: how to lose fat without losing muscle. The combination of GLP-1 agonists with myostatin/activin inhibitors represents the next frontier in metabolic medicine — personalized weight management that optimizes body composition rather than just reducing body weight.
Questions still open
- Will insurance cover the addition of expensive myostatin inhibitors on top of already costly GLP-1 drugs?
- What is the optimal timing for adding muscle-preserving therapy — from the start of weight loss or only after a certain amount has been lost?
Common questions
Am I losing muscle on my GLP-1 medication?
What are myostatin inhibitors?
Read the original research
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.
Metabolism: clinical and experimental, 161, 156057
Citation
Stefanakis, Konstantinos; Kokkorakis, Michail; Mantzoros, Christos S. (2024). The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.. Metabolism: clinical and experimental, 161, 156057. https://doi.org/10.1016/j.metabol.2024.156057